Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Suspension, 0.2%

Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis

Roche receives USFDA’s priority review to Xolair for food allergies based on positive NIH Phase III study results

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure

Wainua granted first-ever regulatory approval in the US for improving neuropathy impairment

US FDA approval based on NEURO-TTRansform Phase III results

Zydus Lifesciences' API site in Ahmedabad. receives 6 observations from USFDA

This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023

Lupin Atlantis Holdings to acquire accretive established products in Europe and Canada from Sanofi

The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired

USFDA grants priority review for Patritumab Deruxtecan in US for certain patients with EGFR-mutated non-small cell lung cancer

If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients

UPM Biomedicals enters into distribution agreement with Brinter for GrowInk bioinks

The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries

Natco Pharma and Breckenridge dismissed from antitrust lawsuit

Norms for fixing prices of medicines

NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201

Venus Remedies' R3SET forays into wellness

The launch of R3SET Detox Candies positions the brand at the forefront of the wellness journey